Actively Recruiting
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-04-14
240
Participants Needed
1
Research Sites
206 weeks
Total Duration
On this page
Sponsors
N
Nanfang Hospital, Southern Medical University
Lead Sponsor
B
Beijing Friendship Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this observational study is to employ single-cell multi-omics and spatial omics technologies to characterize the spatial and immune structures within the livers of patients with fatty liver, hepatic hemangioma, focal nodular hyperplasia, liver fibrosis, cirrhosis, and HBV infection. The primary questions it aims to address are: Investigate the mechanisms of liver degenerative changes during the processes of liver aging, fatty liver, HBV infection, liver fibrosis, and cirrhosis. Characterize the molecular features and cellular networks at different stages of liver degeneration and identify new targets and mechanisms for the cure of the aforementioned diseases. The study will collect peripheral blood and discarded liver tissue from patients with hepatic hemangioma, fatty liver, HBV infection, liver fibrosis, and cirrhosis who are undergoing hepatectomy or liver biopsy.
CONDITIONS
Official Title
Single-cell Multiomics and Spatiotemporal Omics Analyze the Mechanism of Liver Degenerative Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily signed the informed consent form
- No age or gender restrictions
- Diagnosed with hepatic hemangioma or focal nodular hyperplasia of the liver according to relevant guidelines
- Clinically require liver surgery or liver biopsy for hepatic hemangioma, focal nodular hyperplasia, fatty liver, HBV infection, liver fibrosis, or cirrhosis
You will not qualify if you...
- Concurrent infections such as HIV
- Coagulation disorders like hemophilia or idiopathic thrombocytopenic purpura
- Severe underlying diseases affecting immune status
- Investigator considers participant unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nan
Guangzhou, Guangdong, China, 510515
Actively Recruiting
Research Team
Y
Yongyin Li, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here